Sodium Selenite Injectable Vials Recalled for Sterility Assurance Failure
Olympia Compounding Pharmacy recalls 2,333 vials of Sodium Selenite 200 mg/mL injection due to a lack of assurance of sterility. The product was distributed nationwide in the USA, Puerto Rico, and the U.S. Virgin Islands.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable pharmaceutical product where sterility assurance failed, meeting the criterion of a risk-of-harm product where injury has not yet been reported. No illnesses or injuries have been reported in the source text.
Plain-English summary
Olympia Compounding Pharmacy is recalling Sodium Selenite 200 mg/mL injectable vials due to a lack of assurance of sterility. Approximately 2,333 vials were distributed nationwide in the USA, Puerto Rico, and the U.S. Virgin Islands.
The affected lots are L24014 (beyond-use date 6/14/2022) and B24024-22 (beyond-use date 8/24/2022). The product is manufactured by Olympia Compounding Pharmacy at 6700 Conroy Rd., Suite 155, Orlando, FL 32835.
Healthcare providers and patients who have received this product should not use it. Contact Olympia Compounding Pharmacy for instructions on how to return the product and obtain a replacement.
The recalled product
- Product
- Sodium Selenite 200 mg/mL, Multi-Dose 30 mL vial, Rx Only, Olympia Pharmaceuticals, 6700 Conroy Rd., Ste. 155 Orlando, FL 32835, NDC 73198-0074-30
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Category
- Drug — Injectable / Compounded
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: L24014 BUD: 6/14/2022
- B24024-22 BUD: 8/24/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27